Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
90 CHF | +0.99% | +6.48% | +6.04% |
Apr. 24 | BMO Capital Adjusts Price Target on Novartis to $116 From $114, Maintains Market Perform Rating | MT |
Apr. 24 | Novartis Says New Malaria Drug Formulation Safe and Effective for Babies | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.04% | 199B | |
+24.17% | 562B | |
-6.33% | 358B | |
+19.90% | 322B | |
+7.95% | 297B | |
+13.45% | 219B | |
-10.51% | 196B | |
-12.26% | 149B | |
-6.47% | 146B | |
+2.07% | 117B |
- Stock Market
- Equities
- NOVN Stock
- News Novartis AG
- Novartis' : Iptacopan Obtains FDA Breakthrough, Rare Pediatric Disease Designations in Blood, Kidney Disorders